title: Predominant T helper type 2-inflammatory responses promote murine colon cancers.
abstract: Colon cancer is one of the most serious complications of inflammatory bowel diseases, especially ulcerative colitis (UC). Previous studies have shown that characteristic immunological event during inflammation in UC is the expression of T helper-type 2 (Th2) cell-derived cytokines. In this study, we investigated the influence of a predominant Th2-type cytokine response in colitis on carcinogen-induced colon tumors. Wild type (WT), interferon gamma (IFN-gamma) gene deficient (-/-) [Th2 dominant] or interleukin (IL)-4(-/-) [Th1-dominant] mice of BALB/c background were used in this study. To compare tumor formation, mice were given the carcinogen azoxymethane (AOM) and intrarectal administration of trinitrobenzene sulfonic acid (TNBS), to induce colitis. Thirty-three weeks after initial treatment, the total colon was examined. When IFN-gamma(-/-) mice were treated with AOM and TNBS, significantly higher number of tumors were seen (8.4 +/- 1.7) than in WT (3.3 +/- 2.9) or IL-4(-/-) (3.1 +/- 3.4) mice, which received identical treatments. A separate set of experiment, using less doses of AOM and TNBS also showed the higher frequency of tumor formation in IFN-gamma(-/-) mice than in IL-4(-/-) mice. Histologically, the tumors were well- or moderately-differentiated adenocarcinomas. No invasion into the submucosal or serosal layers of the intestine was seen. In immunohistological staining, some tumors in IFN-gamma(-/-) mice showed distinct nuclear expression of beta-catenin, in contrast to the strong membrane staining seen in tumors of IL-4(-/-) mice. In conclusion, colonic inflammation associated with Th2-dominant cytokine responses enhanced the formation of malignant neoplasms.
authors.affiliation: Department of Gastroenterology, Research Institute, International Medical Center of Japan, Tokyo, Japan.
authors.forename: Emi
authors.initials: E
authors.lastname: Osawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
authors.forename: Toshio
authors.initials: T
authors.lastname: Fujisawa
authors.forename: Yuki I
authors.initials: YI
authors.lastname: Kawamura
authors.forename: Noriko
authors.initials: N
authors.lastname: Toyama-Sorimachi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakagama
authors.forename: Taeko
authors.initials: T
authors.lastname: Dohi
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000276:immunology* / Q000473:pathology*; D000818:Animals; D003093:Colitis, Ulcerative / Q000150:complications; D003106:Colon / Q000276:immunology / Q000473:pathology; D003110:Colonic Neoplasms / Q000209:etiology / Q000276:immunology* / Q000473:pathology*; D007249:Inflammation; D007371:Interferon-gamma / Q000235:genetics / Q000502:physiology; D015847:Interleukin-4 / Q000235:genetics / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D009361:Neoplasm Invasiveness; D018418:Th2 Cells / Q000276:immunology*
chemical_list: D015847:Interleukin-4; D007371:Interferon-gamma